Should WEE(1) CHK(1) in on the FAM(122A)ily?

Rebecca Caeser; Triparna Sen

doi:10.1016/j.molcel.2020.10.011

Should WEE(1) CHK(1) in on the FAM(122A)ily?

Mol Cell. 2020 Nov 5;80(3):377-378. doi: 10.1016/j.molcel.2020.10.011.

Authors

Rebecca Caeser¹, Triparna Sen²

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
² Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: sent@mskcc.org.

PMID: 33157011
DOI: 10.1016/j.molcel.2020.10.011

Abstract

Li et al. (2020) elucidate the resistance mechanisms to small-molecule inhibitors targeting the G2/M cell cycle checkpoint kinase, CHK1, in a variety of non-small cell lung cancer cell lines using CRISPR-mediated genetic approaches and identify biomarkers of response.

Publication types

Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Cell Cycle Proteins / genetics
Cell Cycle Proteins / metabolism
Cell Line, Tumor
Checkpoint Kinase 1 / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Phosphorylation
Protein Kinases / metabolism

Substances

Cell Cycle Proteins
Protein Kinases
Checkpoint Kinase 1